Nektar Therapeutics (NKTR) Cash from Investing Activities (2010 - 2026)

Nektar Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$350.8 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 902.92% year-over-year to -$350.8 million; the TTM figure through Mar 2026 stood at -$395.7 million (down 336.93% YoY), while the FY2025 annual figure was -$1.2 million, down 100.84% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$350.8 million, down from $372000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $130.3 million in Q1 2022, with the low at -$350.8 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is $40.6 million (2023), against an average of $17.4 million.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities surged 13521.08% in 2022, then sank 902.92% in 2026.
• Nektar Therapeutics' Cash from Investing Activities stood at $40.0 million in 2022, then tumbled by 56.56% to $17.4 million in 2023, then surged by 246.4% to $60.2 million in 2024, then sank by 99.38% to $372000.0 in 2025, then sank by 94398.12% to -$350.8 million in 2026.
• Business Quant data shows NKTR's Cash from Investing Activities at -$350.8 million in Q1 2026, $372000.0 in Q4 2025, and -$94.9 million in Q3 2025.